{"entity":{"id":"idrx-42","kind":"drug","name":"IDRX-42","aka":["velzatinib - subject to USAN approval"],"tldr":"IDRX-42 is an experimental small-molecule drug from GlaxoSmithKline in phase 3 trials for gastrointestinal stromal tumour, with its target not yet stated publicly.","summary":"IDRX-42 is a small-molecule drug developed by GlaxoSmithKline. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07218926 (A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumours After Imatinib Therapy), in gastrointestinal stromal tumour. The largest, NCT07218926, plans to enrol 450 participants with primary completion expected 2028-05-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of IDRX-42","url":"https://clinicaltrials.gov/search?intr=IDRX-42"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["gist"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["gsk"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07218926"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"small molecule","mechanism":"Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/idrx-42/","neighbours":{"cancer":[{"id":"gist","kind":"cancer","name":"Gastrointestinal stromal tumour (GIST)","route":"/cancers/gist/"},{"id":"gist-imatinib-resistant","kind":"cancer","name":"Imatinib-resistant GIST","route":"/cancers/gist-imatinib-resistant/"},{"id":"gist-kit-exon-11","kind":"cancer","name":"KIT exon 11-mutant GIST","route":"/cancers/gist-kit-exon-11/"},{"id":"gist-pdgfra-d842v","kind":"cancer","name":"PDGFRA D842V-mutant GIST","route":"/cancers/gist-pdgfra-d842v/"}],"company":[{"id":"gsk","kind":"company","name":"GSK","route":"/companies/gsk/"}],"trial":[{"id":"nct07218926","kind":"trial","name":"A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy","route":"/trials/nct07218926/"}]}}